Rawangkan et al. described EGCG as an alternative inhibitor of the PD-1/PD-L1 checkpoint, inhibiting tumor expression of PD-L1 in lung cancer, in vitro, and animal models, via inhibition of IFN-γ and EGF. This evidence concerns the gene CD274 and lung cancer.